Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.60 Consensus Price Target from Brokerages

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have been given a consensus recommendation of “Buy” by the six ratings firms that are covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $25.60.

ATXS has been the subject of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Monday. Oppenheimer upped their price target on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th.

Astria Therapeutics Stock Up 5.7 %

NASDAQ:ATXS opened at $7.79 on Monday. Astria Therapeutics has a twelve month low of $6.94 and a twelve month high of $16.90. The business has a 50 day moving average price of $9.68 and a two-hundred day moving average price of $10.67. The company has a market cap of $439.62 million, a P/E ratio of -3.73 and a beta of 0.70.

Institutional Investors Weigh In On Astria Therapeutics

Several large investors have recently made changes to their positions in ATXS. Quest Partners LLC raised its stake in Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 3,112 shares during the period. PDT Partners LLC bought a new stake in Astria Therapeutics in the 3rd quarter valued at $140,000. SG Americas Securities LLC bought a new stake in Astria Therapeutics in the 3rd quarter valued at $155,000. Hsbc Holdings PLC bought a new stake in Astria Therapeutics in the 2nd quarter valued at $171,000. Finally, Intech Investment Management LLC bought a new position in Astria Therapeutics during the 3rd quarter worth $228,000. Institutional investors and hedge funds own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.